Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Interests for DL are posting on here pushing to keep his status quo.

Those same "interests" might also be reflected in the PTSC Boardroom.

Just because there will continue to be future MMP licenses signed, does not mean the stock of PTSC will have any major price increase.

Under the Status Quo: Until the PTSC BOD starts to meaningfully decrease the 400,000,000 share float, all future earnings from the MMP that may be available for distribution via dividends, will be heavily diluted. The yield capture potential due to the float count will act as a restricter on the stock price, and with such an extremely short lifespan of License recovery remaining, this stock has real challenges in a trade for capital gains environment. The only other option for PTSC stockholders is to hold the stock until the company decides how much (if any) dividends they will pass through to Shareholders and the License fee opportunities are completely exhausted. After that period expires, that will be the end of any financial incentive for us to hold the stock or others to buy our stock.

Folks, we are running out of time, and if some other more friendly and higher fee demanding entity does not prosecute the MMP licenses in a more profitable way than what TPL has done and PTSC may be too fearful to try to change, all the opportunity loses and sit and wait holding of the past 6 years will have been wasted; not to mention our investment capital.

Tell the company to immediately increase Shareholder equity and decrease share availability by buying back company stock through one or more large Tender Offers or Dutch Auctions; it is the one value adding strategy that is completely within our total control and which will result in a magnified and inherently more valuable stock.

Share
New Message
Please login to post a reply